ClinicalTrials.govcontrolled
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
ClinicalTrials.gov study NCT06903273. IPD Sharing: YES. Countries: 1. Publications: 4.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8